Post-transplantation lymphoproliferative disease

QJM: An International Journal of Medicine

Volumn 90, Issue 8, 1997, Pages 497-503

  Savage, P ^a   Waxman, J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT;

DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0030851131     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/90.8.497     Document Type: Review

References (57)

1. McKhann CF. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 1969; 8:209-12.
2. Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1:106-12.
3. Penn I, First MR. Development and incidence of cancer following cyclosporine therapy. Transplantation 1986; 18:210-15.
4. Nalesnick MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J. The pathology of posttransplantation lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Path 1988; 133:173-92.
5. Vogt P, Frei U, Repp H, Bunzendahl H, Oldhafer K, Pichlmayr R. Malignant tumours in renal transplant recipients receiving cyclosporin: Survey of 598 first-kidney transplantations. Nephrol Dial Transplant 1990; 5:282-8.
6. Gaya SBM, Rees AJ, Lechler RI, Williams G, Mason PD. Malignant disease in patients with long-term renal transplants. Transplantation 1995; 59:1705-9.
7. Sheil AGR, Disney APS, Mathew TG, Amiss N, Excell L. Malignancy following renal transplantation. Transplant Proc 1992; 24:1946-7.
8. Penn I. Tumours after renal and cardiac transplantation. Haematol Oncol Clin North Am 1993; 7:431-45.
9. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514-16.
10. Kamel OW, Van de Rijn M, Weiss LM, Del-Zoppo GJ, Hench PK, Robbins BA, Montgomery PG, Warnke RA, Dorfman RF. Reversible lymphomas associated with Epstein-Barr virus occuring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328:1317-21.
11. Liote F, Pertuiset E, Cochand-Priollet B, D'Agay M-F, Dombret H, Numeric P, D'Anglejan G, Kuntz D. Methotrexate related B cell lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. J. Rheumatol 1995; 22:1174-8.
12. Macfarlane GJ, Black RJ. Rheumatoid arthritis and lymphatic cancer. Eur J Cancer 1996; 32A:1630-2.
13. Wilkinson AH, Smith JL, Hunsicker LG, Tobacman J, Kapelanski DP, Johnson M, Wright FH, Behrendt DM, Corry RJ. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation 1989; 47:293-6.
14. Calne RY, Rolles K, White DJG, Thiru S, Evans DB, Henderson R, Hamilton DL, Boone N, McMaster P, Gibby O, Williams R. Cyclosporin-A in clinical organ grafting. Transplant Proc 1981; 13:349-58.
15. Leblond V, Sutton L, Dorent R, Davi F, Bitker M-O, Gabarre J, Charlotte F, Ghoussoub J-J, Fourcade C, Fischer A, Gandjbakhch I, Binet J-L. Raphael M. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995; 13:961-8.
16. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenburg JS, Burke B, Ramsay NKC, McGlave P, Filipovich AH. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71:1234-43.
17. Wood BL, Sabath D, Broudy VC, Raghu G. The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. Cancer 1996; 78:2223-8.
18. Hjelle B, Evans-Holm M, Yen TS, Garovy M, Guis M, Edman JC. A poorly differentiated lymphoma of donor origin in a renal allograft recipient. Transplantation 1989; 47:945-8.
19. Spiro IA, Yandell DW, Li C, Saini S, Ferry J, Powelson J, Katlov WN, Cosimi AB. Brief report; Lymphoma of donor origin occurring in the porta hepatis of a transplanted liver. N Engl J Med 1993; 329:27-9.
20. Frizzera G, Hanto DW, Gajl-Peczalska KJ, Rosai J, McKenna RW, Sibley RK, Holahan KP, Lindquist LL. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41:4262-79.
21. Hanto DW. Classification of Epstein-Barr virus associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies. Ann Rev Med 1995; 46:381-94.
22. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 47:883-9.
23. Cleary ML, Nalesnik MA, Shearer WT, Sklar J. Clonal analysis of transplant associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus. Blood 1988; 72:349-52.
24. Hanto DW, Gajl-Peczalska KJ, Frizzera G, Arthur DC, Balfour HH, McClain K, Simmons RL, Najarian JS. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occuring after renal transplantation. Ann Surg 1983; 198:356-69.
25. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Balfour HH, Simmons R, Najarian JS. Acyclovir therapy of Epstein-Barr virus-induced posttransplant lymphoproliferative diseases. Transplant Proc 1985; 17:89-92.
26. Katz BZ, Raab-Traub N, Miller G. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis 1989; 160:589-98.
27. Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Path 1989; 135:977-87.
28. Klein G. Viral latency and transformation: the strategy of Epstein-Barr virus. Cell 1989; 58:5-8.
29. Edwards RH, Raab-Traub N. Alterations of the p53 gene in Epstein-Barr virus associated immunodeficiency related lymphomas. J Virol 1994; 68:1309-15.
30. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J, Rickinson AB. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991; 349:612-14.
31. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. Induction of BCL-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65:1107-15.
32. Woisetschlaeger M, Strominger JL, Speck SH. Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes. Proc Natl Acad Sci 1989; 86:6498-502.
33. Thorley-Lawson DA. Basic virological aspects of Epstein-Barr virus infection. Semin Hematol 1988; 25:247-52.
34. Rickinson AB, Wallace LE, Epstein MA. HLA-restricted T-cell recognition of Epstein-Barr virus-infected B cells. Nature 1980; 283:865-7.
35. Blazar B, Patarroyo M, Klein E, Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med 1980; 151:614-27.
36. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313:812-15.
37. Schaefer BC, Strominger JL, Speck SH. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci USA 1995; 92:10,565-9.
38. Murray RJ, Kurilla MG, Griffin HM, Brooks JM, Mackett M, Arrand JR, Rowe M, Burrows SR, Moss DJ, Kieff E, Rickinson AB. Human cytotoxic T cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant Vaccinia viruses. Proc Natl Acad Sci USA 1990; 87:2906-10.
39. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV) infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid organ transplant recipients. Blood 1994; 84:972-84.
40. Thomas JA, Hotchin NA, Allday MJ, Amlot P, Rose M, Yacoub M, Crawford DH. Immunohistology of Epstein-Barr virus associated antigens in B cell disorders from immunocompromised individuals. Transplantation 1990; 49:944-53.
41. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321:1080-5.
42. Bird AG, McLachlan SM, Britton S. Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 1989; 289:300-1.
43. Walz G, Zanker B, Melton LB, Suthanthiran M, Strom TB. Possible association of the immunosuppressive and B-cell lymphoma-promoting properties of cyclosporine. Transplantation 1990; 49:191-4.
44. Delecluse HJ, Rouault JP, Ffrench M, Dureau G, Maguad JP, Berger F. Post-transplant lymphoproliferative disorders with genetic abnormalities commonly found in malignant tumours. Br J Haematol 1995; 89:90-7.
45. Crompton CH, Cheung RK, Donjon C, Miyazaki I, Feinmesser R, Hebert D, Dosch HM. Epstein-Barr virus surveillance after renal transplantation. Transplantation 1994; 57:1182-9.
46. Altiok E, Klein G, Zech L, Uno M, Henriksson BE, Battat S, Ono Y, Ernberg I. Epstein-Barr virus transformed pro-B cells are prone to illegitimate recombination between the switch region of the u chain and other chromosomes. Proc Natl Acad Sci USA 1989; 86:6333-7.
47. Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JL. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993; 81:1393-403.
48. Kelly GE, Meikle W, Sheil AGR. Effects of immunosuppressive therapy on the induction of skin tumours by ultraviolet irradiation in hairless mice. Transplantation 1987; 44:429-50.
49. Lein YH, Schroter GPJ, Weil R III, Robinson WA. Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporin-related lymphoma in a renal transplant recipient with acute pancreatitis. Transplantation 1991; 52:739-43.
50. Chen M-C, Gau J-P, Hwang W-L, Young J-H. Combination chemotherapy for posttransplant cyclosporine-related non-Hodgkin's lymphoma. Transplantation 1993; 55:1203.
51. Cohen JI. Epstein-Barr Virus Lymphoproliferative disease associated with acquired immunodeficiency. Medicine 1991; 70:137-60.
52. Calne RY, Rolles K, White DJG, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock G, Henderson RG, Aziz S, Lewis P. Cyclosporin A initially as the only immunosuppresant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2:1033-6.
53. Ho M, Miller G, Atchison RW, Breinig MK, Dummer JS, Andiman W, Starzl TE, Eastman R, Griffith BP, Hardesty RL, Bahnson HT, Hakala TR, Rosenthal JT. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis 1985; 152:876-86.
54. Trigg ME, Finlay JL, Sondel PM. Prophylactic acyclovir in patients receiving bone marrow transplants. N Engl J Med 1985; 312:1708-9.
55. Sixbey JW, Pagano JS. Epstein-Barr virus transformation of human B lymphocytes despite inhibition of viral polymerase. J Virol 1985; 53:299-301.
56. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O'Reilly RJ. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogenic bone marrow transplantation. N Engl J Med 1994; 330:1185-91.
57. Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345:9-13.